Ann: Presentation to 2019 Annual General Meeting, page-2

On remestemcel-L, two sides of the same point.

Something I heard SI say yesterday confirms what I have suspected for quite a while, that the EAP (Expanded Access Program) has been ongoing, it would have been rather inhumane to just stop, despite the cost. For the clinicians already supplying it I suspect it might be a fairly smooth transition one day to the next but probably a lot less paperwork for them, no more urgent EAP applications.

Then there is slide 18 of the AGM presentation, something that has been presented more than once. There would be a moderate pool of professionals in some hospitals who have been using remestemcel-L (as it is now known) for many years, up to a decade for some locations. I suspect the responses expressed are based on quite a few years exposure for most.